Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone. (PubMed, Pharmacopsychiatry) - Jun 11, 2026 - "In conclusion, relatively low concentrations may be sufficient to achieve therapeutic effects across all substances studied, with medical cannabis demonstrating these effects at lower concentrations than typically observed in recreational use. Nevertheless, adverse effects at therapeutic reference ranges cannot be excluded."
Journal • Chemotherapy-Induced Nausea and Vomiting • CNS Disorders • Diabetic Neuropathy • Movement Disorders • Multiple Sclerosis • Neuralgia • Pain • Peripheral Neuropathic Pain
|
|
Frank Petzke; Friederike Amann; Gerald Zernig; Gerhard Gründer; Gudrun Hefner; Peter Cremer-Schaeffer; Ursula Havemann-Reinecke; Winfried Häuser; Xenia M Hart
|